3,883
edits
Changes
Jump to navigation
Jump to search
mLine 1:
Line 1: − + Line 204:
Line 204: − + + + + + + Line 577:
Line 582: − + + + + + + + + + + Line 733:
Line 747: − + + + + + + + + + + + + Line 924:
Line 949: + + + + + + +
MDS, MDS/MPN and MPN Tables: Recurrent Genomic Alterations Detected by Chromosomal Microarray (view source)
Revision as of 17:10, 30 April 2020
, 17:10, 30 April 2020Jennelleh moved page TestMDS-MPNtable to MDS, MDS/MPN and MPN Tables: Recurrent Genomic Alterations Detected by Chromosomal Microarray without leaving a redirect
'''Table 1.''' Evidence for the clinical utility of chromosomal microarray testing (CMA) in myeloid disorders excluding acute myeloid leukemia
'''Table 1 - Evidence for the Clinical Utility of Chromosomal Microarray (CMA) Testing in Myeloid Disorders Excluding Acute Myeloid Leukemia (Literature Review).''' Table derived from Kanagal-Shawanna et al., 2018 [PMID 30377088] with permission from Cancer Genetics.
{| class="wikitable"
{| class="wikitable"
|'''Disease'''
|'''Disease'''
|}
|}
'''Table 2.''' A comprehensive list of CNAs and CN-LOH of known or likely clinical significance in MDS detected by CMA testing
AA, Aplastic anemia; BMFS, Bone Marrow Failure Syndrome; MDS, Myelodysplastic Syndrome; MDS/MPN, Myelodysplastic/ myeloproliferative Neoplasm; MPN, Myeloproliferative Neoplasm; CML, Chronic Myelogeneous Leukemia; sAML, secondary AML; TGA, Total genomic aberration; TKI, tyrosine kinase inhibitors.
∗Recurrent indicates recurrent aberration with no established prognostic significance
'''Table 2 -''' '''A Comprehensive List of Copy Number Aberrations and CN-LOH of Known or Likely Clinical Significance in MDS Detected by CMA Testing (Literature Review).''' Table derived from Kanagal-Shawanna et al., 2018 [PMID 30377088] with permission from Cancer Genetics.
{| class="wikitable"
{| class="wikitable"
|'''Chromosome'''
|'''Chromosome'''
|}
|}
'''Table 3. ''' A comprehensive list of CNAs and CN-LOH of known or likely clinical significance in MDS/MPN detected by CMA testing
Legend: d- diagnostic significance; P-prognostic significance; T- therapeutic significance. Recurrent indicates recurrent aberration with no established prognostic significance.
∗ Clinical significance based on WHO classification using IPSS-R<ref>{{Cite journal|last=Greenberg|first=Peter L.|last2=Tuechler|first2=Heinz|last3=Schanz|first3=Julie|last4=Sanz|first4=Guillermo|last5=Garcia-Manero|first5=Guillermo|last6=Solé|first6=Francesc|last7=Bennett|first7=John M.|last8=Bowen|first8=David|last9=Fenaux|first9=Pierre|date=2012|title=Revised international prognostic scoring system for myelodysplastic syndromes|url=https://www.ncbi.nlm.nih.gov/pubmed/22740453|journal=Blood|volume=120|issue=12|pages=2454–2465|doi=10.1182/blood-2012-03-420489|issn=1528-0020|pmc=4425443|pmid=22740453}}</ref><ref>{{Cite journal|last=Schanz|first=Julie|last2=Tüchler|first2=Heinz|last3=Solé|first3=Francesc|last4=Mallo|first4=Mar|last5=Luño|first5=Elisa|last6=Cervera|first6=José|last7=Granada|first7=Isabel|last8=Hildebrandt|first8=Barbara|last9=Slovak|first9=Marilyn L.|date=2012|title=New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge|url=https://www.ncbi.nlm.nih.gov/pubmed/22331955|journal=Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology|volume=30|issue=8|pages=820–829|doi=10.1200/JCO.2011.35.6394|issn=1527-7755|pmc=4874200|pmid=22331955}}</ref>.
<nowiki>**</nowiki> Isolated trisomy 8 or del(20q) are not diagnostic of MDS in the absence of morphologic findings of disease.
∗∗∗ Potential marker for responsiveness to hypomethylating agents or DNA methyltransferase inhibitors<ref name=":50">{{Cite journal|last=Bejar|first=Rafael|last2=Lord|first2=Allegra|last3=Stevenson|first3=Kristen|last4=Bar-Natan|first4=Michal|last5=Pérez-Ladaga|first5=Albert|last6=Zaneveld|first6=Jacques|last7=Wang|first7=Hui|last8=Caughey|first8=Bennett|last9=Stojanov|first9=Petar|date=2014|title=TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients|url=https://www.ncbi.nlm.nih.gov/pubmed/25224413|journal=Blood|volume=124|issue=17|pages=2705–2712|doi=10.1182/blood-2014-06-582809|issn=1528-0020|pmc=4208285|pmid=25224413}}</ref><ref name=":51">{{Cite journal|last=Traina|first=F.|last2=Visconte|first2=V.|last3=Elson|first3=P.|last4=Tabarroki|first4=A.|last5=Jankowska|first5=A. M.|last6=Hasrouni|first6=E.|last7=Sugimoto|first7=Y.|last8=Szpurka|first8=H.|last9=Makishima|first9=H.|date=2014|title=Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms|url=https://www.ncbi.nlm.nih.gov/pubmed/24045501|journal=Leukemia|volume=28|issue=1|pages=78–87|doi=10.1038/leu.2013.269|issn=1476-5551|pmid=24045501}}</ref>.
'''Table 3''' '''-''' '''A Comprehensive List of Copy Number Aberrations and CN-LOH of Known or Likely Clinical Significance in MDS/MPN Detected by CMA Testing (Literature Review).''' Table derived from Kanagal-Shawanna et al., 2018 [PMID 30377088] with permission from Cancer Genetics.
{| class="wikitable"
{| class="wikitable"
|'''Chromosome'''
|'''Chromosome'''
|}
|}
'''Table 4.''' A comprehensive list of CNAs and CN-LOH of known or likely clinical significance in MPN detected by CMA testing
Legend: d- diagnostic significance; P-prognostic significance; T- therapeutic significance.
Recurrent indicates recurrent aberration with no established significance.
∗ Clinical significance based on International MDS/MPN Working Group recommendations<ref>{{Cite journal|last=Mughal|first=Tariq I.|last2=Cross|first2=Nicholas C. P.|last3=Padron|first3=Eric|last4=Tiu|first4=Ramon V.|last5=Savona|first5=Michael|last6=Malcovati|first6=Luca|last7=Tibes|first7=Raoul|last8=Komrokji|first8=Rami S.|last9=Kiladjian|first9=Jean-Jacques|date=2015|title=An International MDS/MPN Working Group's perspective and recommendations on molecular pathogenesis, diagnosis and clinical characterization of myelodysplastic/myeloproliferative neoplasms|url=https://www.ncbi.nlm.nih.gov/pubmed/26341525|journal=Haematologica|volume=100|issue=9|pages=1117–1130|doi=10.3324/haematol.2014.114660|issn=1592-8721|pmc=4800699|pmid=26341525}}</ref>; No NCCN guidelines available. Low risk (normal, isolated –Y), Intermediate (others), High risk (+8, abnormal 7, complex).
∗∗ Potential marker for responsiveness to hypomethylating agents or DNA methyltransferase inhibitors<ref name=":50" /><ref name=":51" />.
∗∗∗ Haploinsufficiency of 17p as part of an isolated isochromosome may be a distinct disease entity with further increased risk of AML progression relative to 17p loss in a complex karyotype.
'''Table 4''' '''-''' '''A Comprehensive List of Copy Number Aberrations and CN-LOH of Known or Likely Clinical Significance in MPN Detected by CMA Testing (Literature Review).''' Table derived from Kanagal-Shawanna et al., 2018 [PMID 30377088] with permission from Cancer Genetics.
{| class="wikitable"
{| class="wikitable"
|Chromosome
|Chromosome
|<ref name=":41" />
|<ref name=":41" />
|}
|}
Legend: d- diagnostic significance; P-prognostic significance; T- therapeutic significance.
Recurrent indicates recurrent aberration with no established significance.
∗ Clinical significance based on NCCN guidelines<ref>{{Cite journal|last=Mesa|first=Ruben A.|last2=Jamieson|first2=Catriona|last3=Bhatia|first3=Ravi|last4=Deininger|first4=Michael W.|last5=Fletcher|first5=Christopher D.|last6=Gerds|first6=Aaron T.|last7=Gojo|first7=Ivana|last8=Gotlib|first8=Jason|last9=Gundabolu|first9=Krishna|date=2017|title=NCCN Guidelines Insights: Myeloproliferative Neoplasms, Version 2.2018|url=https://www.ncbi.nlm.nih.gov/pubmed/28982745|journal=Journal of the National Comprehensive Cancer Network: JNCCN|volume=15|issue=10|pages=1193–1207|doi=10.6004/jnccn.2017.0157|issn=1540-1413|pmid=28982745}}</ref>; For myelofibrosis, unfavorable [complex karyotype or sole or two abnormalities that include inv(3), 5/5q-, 7/7q-,+8, 11q23 rearrangement, 12p-, and (17q)].
<references />
<references />